fbpx
Pipeline

ATA2271/ATA3271

Atara is developing a mesothelin-targeted autologous CAR T (ATA2271) for advanced mesothelioma and is also developing an off-the-shelf, allogeneic CAR T immunotherapy targeting mesothelin (ATA3271).

ATA2271/ATA3271

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA2271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication Phase
ATA2271: Mesothelioma & other solid tumors Phase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors Preclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer

Global Strategic Collaboration for ATA2271 and ATA3271 With Bayer Continues to Progress with Advancement of the Mesothelin-partnered CAR T Immunotherapy Programs

  • Mesothelin is a target associated with aggressive solid tumors
  • Expresses scFv that binds to mesothelin above cancer threshold
  • Incorporates next-generation CAR T technologies combining novel 1XX costimulatory domain and PD-1 Dominant Negative Receptor (DNR)
  • ATA3271: off-the-shelf, allogeneic EBV mesothelin CAR T, IND-enabling studies ongoing
ATA2271 Phase 1 first cohort enrolled in Q1 2021 for patients with advanced mesothelioma;
ATA3271 IND Submission Expected in H2 2022

Atara’s Next-Generation Solid Tumor CAR T cells:
EBV CAR T Cells Expressing MSLN-1XX CAR and PD1DNR

T and B-cell fractions are separated from a healthy donor via leukapheresis. The CD19+ fraction is transformed with EBV, generating an EBV+ lymphoblastoid cell line (BLCL). T cells are stimulated with BLCLs prior to retroviral introduction of mesothelin (MSLN)-targeted CAR with 1XX signaling domain and PD1DNR. The mesothelin scFv is derived from human anti-MSLN antibody m912. Continued expansion of MSLN-1XX-PD1DNR CAR+ EBV T cells (ATA3271) occurs with BLCL stimulation prior to harvest and cryopreservation for later use.

Next-Generation CAR T Technology

Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T